- Groningen Research Institute of Pharmacy (GRIP), Pharmaceutical Analysis Group: assistant professor (2022- )
- MD Anderson Cancer Center, Dept. of Symptom Research, Houston, TX, USA: postdoctoral researcher (2020-2022)
- Semmelweis University, Dept. of Pharmacology and Pharmacotherapy, Budapest, Hungary: assistant research fellow (2015-2019); assistant professor (2019)
- National Institute of Pharmacy and Nutrition, Budapest, Hungary: external clinical study evaluator (2018)

Research interests: pain; neuropathic pain; cancer pain; opioids; renin-angiotensin system; glycine transporters; neuro-immune interactions.

Medication safety, anticoagulation

Multidrug-resistant tuberculosis; pediatrics

Personalized Acute Medicine

Pharmacokinetic Pharmacodynamic modelling (PKPD)
Modelling & Simulation
Clinical trial design
Pharmacokinetics
Pharmacodynamics
Clinical Pharmacology

Asthma, tuberculosis. (airway) remodelling, inflammation, extracellular matrix, integrins, signalling, therapeutic drug monitoring, toxicology

Neurodegeneration, Mitochondrial function, Inflammation, Potassium channels

Dr. Ghimire is a clinical pharmacology assessor at the Dutch Medical Ethical Review Board (METc Groningen) and a postdoctoral researcher at the University Medical Center Groningen. Her research centers around optimizing tuberculosis (TB) drug treatment and designing clinical trials, with a focus on investigating the relationship between drug doses, exposure, and patient response, integrating both pharmacokinetics and pharmacodynamics components. She has expertise in alternative samples like saliva and dried-blood spots for therapeutic drug monitoring in TB patients. As a co-investigator, she actively contributes to international research projects funded by the EU and national governments, exploring innovative TB treatments to enhance treatment outcomes. Dr. Ghimire's international experience spans several countries, including the Netherlands, Nepal, Spain, Paraguay, Moldova, Belarus, and Ghana. In her role as a clinical pharmacology assessor, she evaluates various aspects of clinical trial protocols, prioritizing drug safety, efficacy, and the quality of investigational drugs, with a specific emphasis on clinical pharmacology.

Reinoud Gosens (1977) is Professor in Translational Pharmacology at the Faculty of Science and Engineering of the University of Groningen. He obtained his PhD in pharmacology in 2004 at the University of Groningen and performed postdoctoral studies at the University of Manitoba, Canada until 2007. His research is focused on the mechanisms that regulate tissue repair and remodeling in asthma and COPD. In particular, the role and therapeutic potential of muscarinic receptors and Wnt/Frizzled receptor signaling  in tissue repair and remodeling are studied.

Global Health
Essential Medicines
Human rights (Right to Health)
Universal access to basic health care (Access to Essential Medicines)
Essential Medicines for Reproductive Health
National Pharmaceutical Policies in developing countries
WHO, UN agencies

Professor Clinical Pharmacy, in particular Oncology-Pharmacy

Hospital and Clinical Pharmacy, clinical pharmacology

Areas of Interest and expertise include diabetes, nephrology, clinical pharmacology

Clinical neuropsychopharmacologist

Targeted Drug Delivery; Microvascular Endothelial Pharmacology; Endothelial Biomedicine; Angiogenesis;  Inflammatory diseases, sepsis, cancer; In vitro-in vivo translation; Drug Development.

Behavior (affective, social, cognitive), Pharmacology, Physiology, Gene expression, microbiome, rat models for depression, rat models for sexual behavior

The translational research focuses on the molecular pharmacological aspects of the development and course of chronic inflammatory diseases. Our motivation for this research focus is very personal, we truly believe that research in the field of translational pharmacology is clustered around molecular partners in defined subcellular compartments (signalosomes) that enables cells to exert highly specialized tasks. Devastating diseases, e.g. cancer, type-II diabetes mellitus, Alzheimers’s dementia, heart failure, asthma, COPD, and infection diseases are associated with defective or derailed signaling processes, and research into the control of these processes clearly is of great public and social importance as well. Currently our research focus lies on chronic inflammatory disorders, and I focus nowadays on experimental models of COPD and related lung disorders, Alzheimer, Parkinson and microbial infections. We successfully undertaken the effort to link the themes to defined subcellular compartments (signalosomes). We linked  novel signaling pathways from membrane receptors towards the recently identified PLC-e isoform, the cAMP sensor Epac. I defined novel and exciting functions of the cytoskeleton driver cofilin, a signal node clearly linked to microbe invasion. I linked this novel clusters to inflammation, remodeling next to the repair of the epithelial barrier and epithelial-to-mesenchymal transition as a mechanism driving fibrosis.

Research unit: Microbes in Health and Disease (MHD)
Research unit: Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE)
Research Institute: GUIDE

Development of non-linear Population Approach Pharmacokinetic and Pharmacodynamic models

Pharmacokinetics

Photopharmacology, Photochemistry

Pharmacokinetics
Pharmacogenetics
Toxicology

Regenerative Pharmacology

Clinical Pharmacology, Albuminuria, Renal function, Clinical Trials